Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 6, p. s82, 2020. DOI: 10.25251/skin.4.supp.82. Disponível em: https://skin.dermsquared.com/skin/article/view/1115. Acesso em: 19 apr. 2025.